Literature DB >> 32232887

FNDC3B 3'-UTR shortening escapes from microRNA-mediated gene repression and promotes nasopharyngeal carcinoma progression.

Ying-Qing Li1, Yang Chen1, Ya-Fei Xu2, Qing-Mei He1, Xiao-Jing Yang1, Ying-Qin Li1, Xiao-Hong Hong1, Sheng-Yan Huang1, Ling-Long Tang1, Na Liu1.   

Abstract

Alternative polyadenylation (APA), which induces shortening of the 3'-UTR, is emerging as an important feature in cancer development and progression. Nevertheless, the effects and mechanisms of APA-induced 3'-UTR shortening in nasopharyngeal carcinoma (NPC) remain largely unclear. Fibronectin type III domain containing 3B (FNDC3B) tended to use proximal polyadenylation site and produce shorter 3'-UTR according to our previous sequencing study. Herein, we found that FNDC3B with shorter 3'-UTR could escape from miRNA-mediated gene repression, and caused its increased expression in NPC. Knocking down of FNDC3B inhibited NPC cell proliferation, migration, invasion, and metastasis in vitro and in vivo. Overexpression of FNDC3B, especially those with shorter 3'-UTR, promoted NPC progression. Furthermore, the mechanism study revealed that FNDC3B could bind to and stabilize myosin heavy chain 9 (MYH9) to activate the Wnt/β-catenin signaling pathway. In addition, MYH9 could reverse the inhibitory effects of FNDC3B knockdown in NPC. Altogether, our results suggested that the 3'-UTR shortening of FNDC3B mRNA mediated its overexpression in NPC and promoted NPC progression by targeting MYH9. This newly identified FNDC3B-MYH9-Wnt/β-catenin axis could represent potential targets for individualized treatment in NPC.
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Entities:  

Keywords:  zzm321990FND3CBzzm321990; alternative polyadenylation; mRNA 3′-UTR shortening; nasopharyngeal carcinoma; proliferation and metastasis

Year:  2020        PMID: 32232887     DOI: 10.1111/cas.14394

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  7 in total

1.  MCL1 alternative polyadenylation is essential for cell survival and mitochondria morphology.

Authors:  Beatriz C Garcia; Ana Curinha; Isabel Pereira-Castro; Ana Neves-Costa; Eduardo Conde-Sousa; Luís F Moita; Alexandra Moreira
Journal:  Cell Mol Life Sci       Date:  2022-03-01       Impact factor: 9.261

2.  Shortening of the KHDRBS1 3'UTR by alternative cleavage and polyadenylation alters miRNA-mediated regulation and promotes gastric cancer progression.

Authors:  Xin Yu; Weibiao Kang; Jiajia Zhang; Changyu Chen; Yi Liu
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

3.  Evaluation of ABCA1 and FNDC3B Gene Polymorphisms Associated With Pseudoexfoliation Glaucoma and Primary Angle-Closure Glaucoma in a Saudi Cohort.

Authors:  Altaf A Kondkar; Tahira Sultan; Taif A Azad; Essam A Osman; Faisal A Almobarak; Glenn P Lobo; Saleh A Al-Obeidan
Journal:  Front Genet       Date:  2022-06-01       Impact factor: 4.772

4.  Circ_0006948 Contributes to Cell Growth, Migration, Invasion and Epithelial-Mesenchymal Transition in Esophageal Carcinoma.

Authors:  Meng Yue; Yanxia Liu; Taiyang Zuo; Yakun Jiang; Jianmei Pan; Shuhong Zhang; Xingjie Shen
Journal:  Dig Dis Sci       Date:  2021-02-25       Impact factor: 3.199

Review 5.  Roles of Major RNA Adenosine Modifications in Head and Neck Squamous Cell Carcinoma.

Authors:  Xing-Xing Huo; Shu-Jie Wang; Hang Song; Ming-de Li; Hua Yu; Meng Wang; Hong-Xiao Gong; Xiao-Ting Qiu; Yong-Fu Zhu; Jian-Ye Zhang
Journal:  Front Pharmacol       Date:  2021-11-25       Impact factor: 5.810

6.  Salidroside suppresses the activation of nasopharyngeal carcinoma cells via targeting miR-4262/GRP78 axis.

Authors:  Shaosheng Liu; Yuanyuan Li; Zhaoxia Li
Journal:  Cell Cycle       Date:  2022-02-27       Impact factor: 5.173

Review 7.  Non-coding RNAs and epithelial mesenchymal transition in cancer: molecular mechanisms and clinical implications.

Authors:  Hashem Khanbabaei; Saeedeh Ebrahimi; Juan Luis García-Rodríguez; Zahra Ghasemi; Hossein Pourghadamyari; Milad Mohammadi; Lasse Sommer Kristensen
Journal:  J Exp Clin Cancer Res       Date:  2022-09-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.